Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.

Bentué-Ferrer D, Tribut O, Polard E, Allain H.

CNS Drugs. 2003;17(13):947-63. Review.

PMID:
14533945
2.

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Nordberg A, Svensson AL.

Drug Saf. 1998 Dec;19(6):465-80. Review. Erratum in: Drug Saf 1999 Feb;20(2):146.

PMID:
9880090
3.

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Jann MW, Shirley KL, Small GW.

Clin Pharmacokinet. 2002;41(10):719-39. Review.

PMID:
12162759
4.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

5.

The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

Inglis F.

Int J Clin Pract Suppl. 2002 Jun;(127):45-63. Review.

PMID:
12139367
6.
7.

The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.

Thompson S, LanctĂ´t KL, Herrmann N.

Expert Opin Drug Saf. 2004 Sep;3(5):425-40. Review.

PMID:
15335298
8.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
10.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

11.

Cholinesterase inhibitors for rarer dementias associated with neurological conditions.

Li Y, Hai S, Zhou Y, Dong BR.

Cochrane Database Syst Rev. 2015 Mar 3;(3):CD009444. doi: 10.1002/14651858.CD009444.pub3. Review.

PMID:
25734590
12.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
13.

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.

Burns A, O'Brien J; BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology.

J Psychopharmacol. 2006 Nov;20(6):732-55. Review.

PMID:
17060346
14.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;4:CD001191.

PMID:
19370562
15.

Pharmacologic treatments of dementia.

Bonner LT, Peskind ER.

Med Clin North Am. 2002 May;86(3):657-74. Review.

PMID:
12171061
16.

Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].

Swedish Council on Health Technology Assessment.

Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun.

17.

Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M.

Ann Intern Med. 2008 Mar 4;148(5):379-97. Review.

PMID:
18316756
18.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504. doi: 10.1002/14651858.CD006504.pub2. Review.

PMID:
22419314
19.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
20.

Supplemental Content

Support Center